Form 3 Cerevel Therapeutics For: Sep 10 Filed by: PF Equity Holdings 1 B.V.
Tweet
Share
E-mail| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||||||
1. Name and Address of Reporting Person
*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 09/10/2021 |
3. Issuer Name
and
Ticker or Trading Symbol
Cerevel Therapeutics Holdings, Inc. [ CERE ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check
Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock (1) | 27,349,211 | ||
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Explanation of Responses: |
| 1. Shares acquired from its parent entity, Pfizer Inc. for no cash consideration. |
| Remarks: |
| poa1n.htm |
| Susan E. Grant, Attorney-in-fact on behalf of PF Equity Holdings 1 B.V. | 09/20/2021 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
PF Equity Holdings 1 B.V.
POWER OF ATTORNEY
Know all by these presents that PF Equity Holdings 1 B.V. ("Company') hereby constitutes and appoints each of Tara J. Gabbai, Susan E. Grant, Madelyn D. Purcell and Shehzad Siddiqui as the undersigned's true and lawful attorney-in-fact and agent, to:
1. on behalf of the undersigned submit to U.S. Securities and Exchange Commission (the "SEC") a Form ID including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules and regulations promulgated thereunder; Schedule 13D in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, a joint filing agreement in accordance with Rule 13d-1(k) (1) under the Exchange Act and any amendments to the foregoing:
2. do and perform any and all acts for and of behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, Schedule 13D or Schedule 13G, as applicable, or joint filing agreement, complete and execute any amendment or amendments thereto, and timely file such form, schedule or agreement with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
3. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of or legally required by the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve to such attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation; hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact in serving in such capacity at the request of the undersigned, are not assuming any of the undersigned responsibilities to comply with Section 13 or Section 16 of the Exchange Act as applicable.
This Power of Attorney share remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 or Schedule 13D of Schedule 13G as applicable with respect to the undersigned's holdings of and transactions in securities, unless earlier revoked by the undersigned in a signed writing deliver to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.
Date: September 10, 2021
PF Equity Holdings 1 B.V.
Signature: /s/ Eduard Slijkoord
Name: Eduard Slijkoord
Title: Managing Director B
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerevel Therapeutics Holdings (CERE) Reports Positive Topline Results for Tavapadon
- Nitric Acid Market to Reach USD 36.62 Billion by 2031, Driven by Surging Demand for Fertilizers and Lightweight Vehicles
- Tower Adopts Structural Model Connecting the Widespread Orogenic Gold Mineralization Intersected at Rabbit North and Prepares to Drill Systematically through 2024
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
